{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:55:37Z","timestamp":1770742537207,"version":"3.49.0"},"reference-count":37,"publisher":"Informa UK Limited","issue":"6","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2023,7,3]]},"DOI":"10.1080\/14737167.2023.2200167","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T08:33:55Z","timestamp":1680770035000},"page":"651-658","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL)"],"prefix":"10.1080","volume":"23","author":[{"given":"Hetalkumari","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy, UT Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svea K.","family":"Wahlstrom","sequence":"additional","affiliation":[{"name":"US Medical Affair, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Kunzweiler","sequence":"additional","affiliation":[{"name":"formerly of Analysis Group, Inc, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Castriota","sequence":"additional","affiliation":[{"name":"formerly of Analysis Group, Inc, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Chang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqian","family":"Gu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Guo","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellie J.","family":"Ryan","sequence":"additional","affiliation":[{"name":"US Medical Affair, AstraZeneca Pharmaceuticals, Gaithersburg, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"cit0001","unstructured":"American Cancer Society. What Is chronic lymphocytic leukemia? 2022 [cited 2022 Feb 10]. Available from: https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/about\/what-is-cll.html"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0367-7"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1097\/01.mjt.0000104489.93653.0f"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25595"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.208603"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17184"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211073906"},{"key":"cit0008","unstructured":"Abbvie Inc. FDA approves imbruvica (ibrutinib) for the first-line treatment of chronic lymphocytic leukemia: Drugs.com; 2016 [cited 2020 Feb 14]. Available from: https:\/\/www.drugs.com\/newdrugs\/fda-approves-imbruvica-ibrutinib-first-line-chronic-lymphocytic-leukemia-4353.html"},{"key":"cit0009","unstructured":"United States Food and Drug Administration. FDA approves imbruvica (ibrutinib) to treat chronic lymphocytic leukemia: Drugs.com; 2014 [cited 2020 Feb 14]. Available from: https:\/\/www.drugs.com\/newdrugs\/fda-approves-imbruvica-ibrutinib-chronic-lymphocytic-leukemia-4007.html"},{"key":"cit0010","unstructured":"United States Food and Drug Administration. Labeling-Package Insert: iMBRUVICA\u00ae (ibrutinib) 2020 [cited 2022 Jan 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/205552s033,210563s010lbl.pdf"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-716977"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.06.016"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509981"},{"key":"cit0018","unstructured":"United States Food and Drug Administration. Labeling-Package Insert: cALQUENCE\u00ae (acalabrutinib) 2019 [cited 2022 Jan 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210259s006s007lbl.pdf"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03355"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913144"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01252-y"},{"key":"cit0023","unstructured":"United States Food and Drug Administration. Labeling-package insert: venclexta\u00ae (venetoclax) 2019 [cited 2022 Jan 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208573s011s014s015lbl.pdf"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000120"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"issue":"3","key":"cit0028","first-page":"27","volume":"5","author":"Wong JCW","year":"2019","journal-title":"Value Outcomes Spotlight"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-21-00460"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1001\/amajethics.2021.639"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"cit0032","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022)","author":"Peryer G","year":"2022"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.11648\/j.ajtas.20160501.11"},{"key":"cit0034","unstructured":"United States Bureau of Labor Statistics. [cited 2020 Feb 14]. Available from: https:\/\/www.bls.gov\/oes\/"},{"issue":"8","key":"cit0035","first-page":"50","volume":"101","author":"Eltorai AEM","year":"2018","journal-title":"R I Med J"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01439"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25851"}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737167.2023.2200167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T05:36:14Z","timestamp":1687412174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737167.2023.2200167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,7,3]]}},"alternative-id":["10.1080\/14737167.2023.2200167"],"URL":"https:\/\/doi.org\/10.1080\/14737167.2023.2200167","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}